SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

$RPID
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $RPID alert in real time by email
SC 13G/A 1 tm235737d1_sc13ga.htm SC 13G/A

 

 

 

Securities and Exchange Commission

Washington, D.C. 20549

 

Schedule 13G

 

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

(Amendment No. 1)*

 

Rapid Micro Biosystems, Inc.

(Name of Issuer)

 

Class A Common Stock

(Title of Class of Securities)

 

75340L104

(CUSIP Number)

 

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)
¨Rule 13d-1(c)
xRule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 75340L104Schedule 13GPage 1 of 6

 

1 Names of Reporting Persons

Colony Harvest Ltd.
2 Check the Appropriate Box if a Member of a Group (a) ¨
(b) ¨
3

SEC Use Only 

 

4 Citizenship or Place of Organization

Cayman Islands
Number of Shares
Beneficially Owned
by Each Reporting
Person With
5

Sole Voting Power

 

0

 

6

Shared Voting Power

 

1,622,260

 

7

Sole Dispositive Power

 

0

 

8

Shared Dispositive Power

 

1,622,260

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,622,260

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

4.5%

12

Type of Reporting Person

 

CO

         

 

CUSIP No. 75340L104Schedule 13GPage 2 of 6

 

1 Names of Reporting Persons

Fares Zahir
2 Check the Appropriate Box if a Member of a Group (a) ¨
(b) ¨
3

SEC Use Only 

 

4 Citizenship or Place of Organization

Malaysia
Number of Shares
Beneficially Owned
by Each Reporting
Person With
5

Sole Voting Power

 

0

 

6

Shared Voting Power

1,622,260

 

7

Sole Dispositive Power

 

0

 

8

Shared Dispositive Power

 

1,622,260

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,622,260

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

4.5%

12

Type of Reporting Person

 

IN

         

 

CUSIP No. 75340L104Schedule 13GPage 3 of 6

 

ITEM 1.(a)           Name of Issuer:

 

Rapid Micro Biosystems, Inc. (the “Issuer”).

 

(b)Address of Issuer’s Principal Executive Offices:

 

1001 Pawtucket Boulevard West, Suite 280, Lowell, MA 01854

 

ITEM 2.(a)           Name of Person Filing:

 

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

 

Colony Harvest Ltd.

Fares Zahir

 

(b)Address or Principal Business Office:

 

The principal business address for the Reporting Persons is 26.03-26.08, Level 26, GTower, No. 199, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia.

 

(c)Citizenship of each Reporting Person is:

 

Colony Harvest Ltd. is organized under the laws of the Cayman Islands. Fares Zahir is a citizen of Malaysia.

 

(d)Title of Class of Securities:

 

Class A Common Stock, par value $0.01 per share (“Class A Common Stock”).

 

(e)CUSIP Number:

 

75340L104

 

ITEM 3.

 

Not applicable.

 

ITEM 4.Ownership.

 

(a-c)

 

The ownership information presented below represents beneficial ownership of Class A Common Stock of the Issuer as of December 31, 2022, based upon 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022.

 

 

CUSIP No. 75340L104Schedule 13GPage 4 of 6

 

Reporting Person 

Amount

beneficially

owned

  

Percent

of class:

   Sole power to vote or to direct the vote:   Shared power to vote or to direct the vote:  

Sole power to dispose or to direct the disposition

of:

  

Shared

power to

dispose or

to direct

the

disposition

of:

 
Colony Harvest Ltd.   1,622,260    4.5%   0    1,622,260    0    1,622,260 
Fares Zahir   1,622,260    4.5%   0    1,622,260    0    1,622,260 

 

Colony Harvest Ltd. is the record holder of the shares of Class A Common Stock reported herein. Fares Zahir is the director of Colony Harvest Ltd. and may be deemed to share beneficial ownership over the securities reported herein.

 

ITEM 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following: x

 

ITEM 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

ITEM 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

ITEM 9.Notice of Dissolution of Group.

 

Not applicable.

 

ITEM 10.Certification.

 

Not applicable.

 

 

CUSIP No. 75340L104Schedule 13GPage 5 of 6

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 8, 2023

 

  Colony Harvest Ltd.

 

By:/s/ Fares Zahir
Name:Fares Zahir
Title:Director

 

  Fares Zahir

 

  /s/ Fares Zahir

 

 

CUSIP No. 75340L104Schedule 13GPage 6 of 6

 

LIST OF EXHIBITS

 

Exhibit No. Description
99 Joint Filing Agreement (previously filed).

 

 

 

Get the next $RPID alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RPID

DatePrice TargetRatingAnalyst
2/12/2025$8.00Overweight
KeyBanc Capital Markets
8/16/2022Overweight → Neutral
JP Morgan
3/7/2022$11.00 → $10.00Equal-Weight
Morgan Stanley
2/15/2022$24.00 → $11.00Equal-Weight
Morgan Stanley
11/15/2021$26.00 → $24.00Equal-Weight
Morgan Stanley
8/9/2021Outperform
Cowen
8/9/2021$26.00Equal-Weight
Morgan Stanley
8/9/2021$28.00Buy
Stifel
More analyst ratings

$RPID
Press Releases

Fastest customizable press release news feed in the world

See more
  • Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units ("RSUs") of the Company's Class A common stock ("Common Stock") as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the "Options") and 174,000 RSUs as a material inducement to employment to two

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

    Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany

    LEXINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it has entered into a five-year global distribution and collaboration agreement (the "Agreement") with the Life Science business of Merck KGaA , Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). The agreement grants MilliporeSigma global co-exclusive rights to sell Growth Direct systems and related consumables. MilliporeSigma

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$RPID
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RPID
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$RPID
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RPID
SEC Filings

See more

$RPID
Leadership Updates

Live Leadership Updates

See more
  • Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

    LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

    LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Reaction Biology Announces Appointment of Richard S. Kollender to Chief Financial Officer and Chief Business Officer

    MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology.  "Having managed large, global biopharmaceut

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$RPID
Financials

Live finance-specific insights

See more
  • Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

    Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025

    LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:00 a.m. ET on Friday, February 28, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results

    Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 2

    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$RPID
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more